Market cap
₹58,866 Cr
Recently Viewed
Clear AllNSE: LAURUSLABS | BSE: 540222
₹1,090.45
₹-33.10
(-2.95%)
As on 28-Apr-2026IST
Market cap
₹58,866 Cr
Revenue (TTM)
₹6,722 Cr
P/E Ratio
69.8
P/B Ratio
11.6
Div. Yield
0.1 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹843 Cr
ROE
8.3 %
ROCE
10.2 %
Industry P/E
46.73
EV/EBITDA
34.1
Debt to Equity
0.6
Book Value
₹93.7
EPS
₹15.6
Face value
2
Shares outstanding
539,856,582
CFO
₹5,406.87 Cr
EBITDA
₹8,501.77 Cr
Net Profit
₹3,977.62 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Laurus Labs
| -1.6 | 8.1 | 9.0 | 74.3 | 55.1 | 18.5 | -- |
|
BSE Healthcare
| 2.6 | 5.0 | 8.0 | 6.4 | 25.0 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Laurus Labs
| 80.0 | 39.2 | 14.6 | -30.4 | 52.5 | 379.5 | -6.1 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Laurus Labs
|
1,090.5 | 58,866.0 | 6,721.6 | 841.8 | 18.1 | 18.2 | 69.8 | 11.6 |
| 2,467.8 | 20,207.0 | 1,215.1 | 284.8 | 28.7 | 21.1 | 70.4 | 13.3 | |
| 2,403.7 | 67,867.9 | 16,468.1 | 1,065.0 | 23.2 | 26.6 | 63.7 | 6.8 | |
| 705.2 | 17,470.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 32 | 3.9 | |
| 942.5 | 14,987.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 34.6 | 2.3 | |
| 1,094.1 | 19,596.4 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.6 | 2.2 | |
| 1,763.0 | 20,205.8 | 1,419.3 | 20.1 | 8.4 | 0.5 | 1005.2 | 3.5 | |
| 164.5 | 21,839.6 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.8 | |
| 440.3 | 17,729.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 50.4 | 3.7 | |
| 1,417.3 | 23,027.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1046.7 | 5.0 |
Laurus Labs: What hinders its growth?
3 min read•By Hemkesh Khattar
Companies falling short of cash
2 min read•By Rajan Gulati
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV),... antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India. Read more
Incorporated
2005
Chairman
Ravindranath Kancherla
Managing Director
--
Headquarters
Vishakhapatnam, Andhra Pradesh
Website
Looking for more details about Laurus Labs Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Laurus Labs Ltd is ₹1,090.45 (NSE) and ₹1,090.40 (BSE) as of 28-Apr-2026 IST. Laurus Labs Ltd has given a return of 55.14% in the last 3 years.
The P/E ratio of Laurus Labs Ltd is 69.80 times as on 28-Apr-2026, a 49 premium to its peers’ median range of 46.73 times.
The P/B ratio of Laurus Labs Ltd is 11.64 times as on 28-Apr-2026, a 214 premium to its peers’ median range of 3.71 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
92.37
|
7.44
|
|
2024
|
133.90
|
5.16
|
|
2023
|
20.12
|
3.92
|
|
2022
|
38.31
|
9.49
|
|
2021
|
19.75
|
7.49
|
The 52-week high and low of Laurus Labs Ltd are Rs 1,144.85 and Rs 572.25 as of 28-Apr-2026.
Laurus Labs Ltd has a market capitalisation of ₹ 58,866 Cr as on 28-Apr-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Laurus Labs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.